Oct 23, 2018
Invitation - Presentation of Sobi's Q3 2018 Results
Oct 10, 2018
New Chief Medical Officer Joins Inceptua
Sep 05, 2018
Strong Industry Profiles Join Inceptua
Aug 23, 2018
Sobi(TM) Completes Acquisition of the Global Rights for Emapalumab From Novimmune
Aug 10, 2018
First Patient Dosed in Phase 1/2 Study Evaluating SOBI003 for Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)
Jul 27, 2018
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe
May 21, 2018
Sobi Emphasises Commitment to Haemophilia Community at WFH 2018 World Congress
Apr 19, 2018
Invitation - Presentation of Sobi's Q1 2018 Results
Apr 16, 2018
World Hemophilia Day 2018: Sharing Knowledge Makes Us Stronger
Apr 16, 2018
Grifols donates over 25 million international units of blood clotting factor in 2017
Feb 28, 2018
Sobi Launches Enhanced Corporate Sustainability Initiative
Feb 26, 2018
Henrik Stenqvist is Joining Sobi(TM) as New Chief Financial Officer
Feb 12, 2018
Research Study Results Presented at EAHAD 2018
Feb 07, 2018
Time to Elevate Protection in Haemophilia Care: New Data From Sobi(TM)
Feb 07, 2018
The Republic of Ireland Switches all People With Haemophilia A & B Treated With Replacement Clotting Factors to Sobi's(TM) Extended Half-life Therapies
Jan 26, 2018
World Federation of Hemophilia World Bleeding Disorders Registry GOES LIVE January 26, 2018
Jan 23, 2018
FDA Accepts Investigational New Drug Application and Grants Fast Track Status for SOBI003 for the Treatment of MPS IIIA
Nov 16, 2017
Sobi(TM) - First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Still's Disease
Nov 10, 2017
Medivir Appoints Christina Herder as Executive Vice President Strategic Business Development
Nov 06, 2017
Market Access Impact: Haemophilia B (EU5)